Summary Background Sex workers are disproportionately affected by HIV compared with the general population. Most studies of HIV risk among sex workers have focused on individual-level risk factors, with few studies assessing potential structural determinants of HIV risk. In this Article, we examine whether criminal laws around ...

PARIS, February 02, 2017 – ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, announced today that the previously disclosed results of its two Phase I trials with ABX464 in healthy volunteers have now been ...

U.S. FDA grants priority review to AbbVie for its investigational regimen of glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) – If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major ...

In first-ever study, Case School of Medicine researchers to pair monoclonal antibody with body’s own killer-cell stimulator Newswise — A Case Western Reserve University School of Medicine researcher has received a $2.5 million grant from Gilead Sciences, a California-based biopharmaceutical company, to see if two so-far ...

A research team at UNMC has used a process they call LASER ART (long-acting slow effective release antiretroviral therapy) to discover an unexpected pathway to open cell storage areas for antiviral drugs. The discovery could revolutionize current treatments for HIV/AIDS by extending the actions of ...

The Global Review Panel on the Future of the UNAIDS Joint Programme Model has launched a virtual consultation that will run until 10 February. The panel is seeking input on how the Joint Programme can be refined and reinforced to better support countries to end ...

Fast-track the end of AIDS in the EU – practical evidence-based interventions In a two-day conference organised in collaboration between the Maltese Presidency of the Council of the European Union and ECDC, HIV experts from across the European Union discuss how to reverse this trend and ...

The Lancet HIV is an exclusively online journal dedicated to publishing original research that advocates change in, or illuminates, HIV clinical practice. It publishes translational, epidemiological, clinical, operational, and implementation studies. The February 2017 issue is available here. Source

Only a minority of centres have specialist clinics for management of co-morbidities Two-thirds of HIV clinics in the UK do not think there is a current need for specialist care services targeted at older adults, investigators report in HIV Medicine. “This is important as, although there ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for RG-101 remains on clinical hold. In ...

No new HIV infections have been seen among nearly 1000 people who started Truvada for pre-exposure prophylaxis (PrEP) at Kaiser Permanente Northern California, according to a recent report in the Journal of Acquired Immune Deficiency Syndromes. The most recent analysis shows, however, that incidence of ...

The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales. Epclusa – a once-daily, fixed-dose combination of the nucleotide ...

Currently most effective directly-acting antiviral agent for hepatitis C (HCV) treatment has already arrived to Ukraine! Alliance for Public Health launches the third phase of HCV treatment program for key populations. This phase stipulates using a direct-acting antiviral agent, which is new for Ukraine – Harvoni ...

Study finds good nutrition improves medication adherence and mental health HIV-positive people who received healthy food and snacks for six months were more likely to adhere to their medication regimens, and they, as well as people with type 2 diabetes, were less depressed and less likely ...

Fervid research has uncovered dozens of antibodies that shield cells from HIV. These broadly neutralizing antibodies (bNAbs) protect monkeys from SHIV, the simian-HIV hybrid. Thousand-person human trials are already dripping bNAbs into high-risk men and women to see if they prevent HIV infection. And much ...

A team led by UCL researchers has identified how HIV is able to infect macrophages, a type of white blood cell integral to the immune system, despite the presence of a protective protein. They discovered a treatment that can maintain macrophage defences which could be ...

Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body’s ability to control it. But a small group of infected individuals—called elite controllers—possess immune systems capable of defeating the virus. They accomplish ...

In an effort to improve the international response to combatting multidrug-resistant TB, MPP and Johns Hopkins University sign licensing agreement for investigational treatment sutezolid Geneva, 25 January 2017 — The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University ...